Type in a keyword and see the report right away. Explore your online world!
If you have already a Newsmeter account:
You can free sign up for Newsmeter:
x
In this episode, Megan Thomas is in conversation with Steve Worland, CEO of eFFECTOR, a company targeting distinct targets central to the eIF4F translation initiation complex.
SynOx Therapeutics has closed a $75m Series B financing round, which will be used to generate registrational Phase III clinical and CMC data for emactuzumab, the company’s potentially best-in-class CSF-1(R) inhibiting monoclonal antibody (mAb) for the treatment of tenosynovial giant cell tumour (TGCT).
Recombinant adeno-associated viruses (rAAVs) are considered a promising delivery system for gene therapy medicines.
The leading news story this week has been the launch of a new clinical trial in the UK for a melanoma personalised mRNA cancer vaccine, but there have been a number of other interesting developments in cancer drug discovery.
The last couple of months has seen a number of changes in senior roles in the drug discovery sector.
Myeloma Patients Europe (MPE) has launched a new online tool to facilitate the search of clinical trials in myeloma.
DDW Editor Reece Armstrong and Multimedia Editor Megan Thomas attended LSX World Congress from 29-30 April in London, UK. Having attended a range of sessions and spoken to industry attendees, they reflect on the biotech arm of the event.
Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM).
Join DDW for this free event to hear from the experts on the innovation and opportunity in the therapeutic antibody market.
Hailed as a revolution in the treatment of many diseases, cell and gene therapy (CGT) is the fastest growing area of therapeutics.
DDW’s Megan Thomas speaks to industry experts and thought leaders about the potential for therapeutic antibodies in 2024.
Download this exclusive eBook to learn more about the impact of mAbs on drug discovery and the range of applications for mAbs.
Traditional drug discovery is time-consuming, and expensive, and numerous industry studies are showing a year-on-year decrease in return on investment from R&D efforts across the board.
Glen Clova Scientific has closed a £4 million (approximately $5 million) seed financing round, led by Norcliffe Capital together with investment from DSW Ventures, TRICAPITAL Angels and Scottish Enterprise.
A drop in the prices of non-human primates (NHPs) in China indicates a post-pandemic slowdown in Chinese drug development, according to a report in the Financial Times.
